Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5CNS 5NET 3Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 2Pheochromocytoma 1Paraganglioma 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Head and Neck Neoplasms 1

Interventions

spartalizumab 1pembrolizumab 1guadecitabine 1gallium Ga 68 dotatate 1belzutifan 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Genetic Testing 1Fluorodeoxyglucose F18 1Everolimus 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × gallium Ga 68 dotatate × Genitourinary × Clear all
NCT06479811 2026-04-28

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
120 enrolled
CNSEndocrineGenitourinaryHead & Neck

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡